Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

Summary:

High-dose chemotherapy and autologous stem cell transplantation are used increasingly to treat patients with light-chain-related amyloidosis (AL). Treatment-related mortality is approximately 15%. To enable more patients to undergo stem cell transplantation, a risk-adapted strategy has been developed to treat with lower chemotherapy doses those patients who are at excessive risk. It is unclear whether reducing the chemotherapy dose in patients at excessive risk of treatment toxicity reduces the overall response. We retrospectively reviewed 171 AL patients who underwent conditioning chemotherapy with stem cell transplantation. The patients comprised two groups: those receiving standard high-dose melphalan and those receiving intermediate-dose melphalan. Responses were categorized as hematologic response, which used criteria for myeloma response. The two groups showed statistically significant differences; the overall response rates were 75% in the high-dose group and 53% in the intermediate-dose group although treatment-related mortality was the same in both groups. Reducing the melphalan dose appeared to render more AL patients eligible for stem cell transplantation but sacrificed an element of response. Methods are needed to reduce treatment-related toxicity so that more patients can receive full-dose conditioning chemotherapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Perfetti V, Vignarelli MC, Casarini S et al. Biological features of the clone involved in primary amyloidosis (AL). Leukemia 2001; 15: 195–202.

    Article  CAS  PubMed  Google Scholar 

  2. Kyle RA . Clinical aspects of multiple myeloma and related disorders including amyloidosis. Pathol Biol (Paris) 1999; 47: 148–157.

    CAS  Google Scholar 

  3. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662–3670.

    CAS  PubMed  Google Scholar 

  4. Dispenzieri A, Lacy MQ, Kyle RA et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350–3356.

    Article  CAS  PubMed  Google Scholar 

  5. Comenzo RL, Gertz MA . Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282.

    Article  CAS  PubMed  Google Scholar 

  6. Comenzo RL, Sanchorawala V, Fisher C et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999; 104: 553–559.

    Article  CAS  PubMed  Google Scholar 

  7. Elghetany MT, Saleem A . Methods for staining amyloid in tissues: a review. Stain Technol 1988; 63: 201–212.

    Article  CAS  PubMed  Google Scholar 

  8. Kaplan B, Vidal R, Kumar A et al. Immunochemical microanalysis of amyloid proteins in fine-needle aspirates of abdominal fat. Am J Clin Pathol 1999; 112: 403–407.

    Article  CAS  PubMed  Google Scholar 

  9. Moreau P, Facon T, Attal M et al, for the Intergroupe Francophone du Myelome. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735.

    Article  CAS  PubMed  Google Scholar 

  10. Bladé J, Samson D, Reece D et al, for the Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant) Chronic Leukaemia Working Party and the Myeloma Working Committee of the IBMTR (International Bone Marrow Transplant Registry) and ABMTR (Autologous Blood and Marrow Transplant Registry). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.

    Article  PubMed  Google Scholar 

  11. Bradwell AR, Carr-Smith HD, Mead GP et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489–491.

    Article  PubMed  Google Scholar 

  12. Abraham RS, Katzmann JA, Clark RJ et al. Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 274–278.

    Article  CAS  PubMed  Google Scholar 

  13. Henon P, Sovalat H, Bourderont D et al. Role of the CD34+ 38− cells in posttransplant hematopoietic recovery. Stem Cells 1998; 16 (Suppl. 1): 113–122.

    PubMed  Google Scholar 

  14. Murray S . Using weighted Kaplan–Meier statistics in nonparametric comparisons of paired censored survival outcomes. Biometrics 2001; 57: 361–368.

    Article  CAS  PubMed  Google Scholar 

  15. Gertz MA, Kyle RA, Greipp PR . Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257–262.

    CAS  PubMed  Google Scholar 

  16. Jones NF, Hilton PJ, Tighe JR, Hobbs JR . Treatment of ‘primary’ renal amyloidosis with melphalan. Lancet 1972; 2: 616–619.

    Article  CAS  PubMed  Google Scholar 

  17. Child JA, Morgan GJ, Davies FE et al, for the Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  18. Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637–642.

    Article  CAS  PubMed  Google Scholar 

  19. Dember LM, Sanchorawala V, Seldin DC et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001; 134: 746–753.

    Article  CAS  PubMed  Google Scholar 

  20. Saba N, Sutton D, Ross H et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853–855.

    Article  CAS  PubMed  Google Scholar 

  21. Gertz MA, Lacy MQ, Dispenzieri A et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002; 113: 549–555.

    Article  CAS  PubMed  Google Scholar 

  22. Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766–769.

    Article  CAS  PubMed  Google Scholar 

  23. Sanchorawala V, Wright DG, Seldin DC et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002; 117: 886–889.

    Article  CAS  PubMed  Google Scholar 

  24. McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822–824.

    Article  CAS  PubMed  Google Scholar 

  25. Selby PJ, McElwain TJ, Nandi AC et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55–62.

    Article  CAS  PubMed  Google Scholar 

  26. Gertz MA, Kyle RA, Greipp PR et al. Beta 2-microglobulin predicts survival in primary systemic amyloidosis. Am J Med 1990; 89: 609–614.

    Article  CAS  PubMed  Google Scholar 

  27. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.

    Article  CAS  PubMed  Google Scholar 

  28. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  PubMed  Google Scholar 

  29. Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.

    CAS  PubMed  Google Scholar 

  30. San Miguel JF, Lahuerta JJ, Garcia-Sanz R et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000; 1: 28–36.

    Article  CAS  PubMed  Google Scholar 

  31. Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310–1313.

    Article  CAS  PubMed  Google Scholar 

  32. Skinner M, Sanchorawala V, Seldin DC et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93.

    Article  CAS  PubMed  Google Scholar 

  33. Lachmann HJ, Gallimore R, Gillmore JD et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78–84.

    Article  CAS  PubMed  Google Scholar 

  34. Palladini G, Perfetti V, Obici L et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the Hematologic Malignancies Fund, Mayo Clinic, Rochester, Minnesota.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M A Gertz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gertz, M., Lacy, M., Dispenzieri, A. et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 34, 1025–1031 (2004). https://doi.org/10.1038/sj.bmt.1704691

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704691

Keywords

This article is cited by

Search

Quick links